Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

451
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
451
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

461
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
461
  1. 首页
  3. 针对联合呼吸道疾病的新型药物外体免疫疗法:plga封装的,带有ppar-γ激动剂的介质干细胞外体治疗过敏性鼻炎和喘
  1. 首页
  3. 针对联合呼吸道疾病的新型药物外体免疫疗法:plga封装的,带有ppar-γ激动剂的介质干细胞外体治疗过敏性鼻炎和喘

相关实验视频

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells
12:08

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells

Published on: March 10, 2016

11.3K

针对联合呼吸道疾病的新型药物外体免疫疗法:PLGA封装的,带有PPAR-γ激动剂的介质干细胞外体治疗过敏性鼻炎和喘

Khawar Ali Shahzad1,2, Zhao Wang1, Boyu Cai1

  • 1Department of ORL-HNS, Shanghai Fourth People's Hospital, and School of Medicine, Tongji University, Shanghai, China.

Stem cell research & therapy
|September 2, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

这项研究引入了一种新的纳米颗粒输送外体疗法 (PLGA-exo-PIO) 治疗联合呼吸道疾病. 在过敏性鼻炎和喘模型中,治疗有效降低了炎症和改善症状.

关键词:
过敏性鼻炎喘症外体细胞口路径其他皮奥格利塔

更多相关视频

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

相关实验视频

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells
12:08

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells

Published on: March 10, 2016

11.3K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

科学领域:

  • 复原医学
  • 免疫疗法
  • 纳米技术

背景情况:

  • 联合呼吸道疾病 (UAD),如过敏性鼻炎和喘,导致严重的发病率.
  • 常规治疗提供症状缓解, 但干细胞衍生外体等细胞疗法对呼吸道疾病具有前景.

研究的目的:

  • 研究一种新药外体免疫疗法的治疗效果和机制.
  • 这种疗法涉及中干细胞衍生的外体 (MSC-exo) 增强PIO,并通过PLGA纳米颗粒 (PLGA-exo-PIO) 治疗过敏呼吸道疾病.

主要方法:

  • 使用雄性Balb/ c小鼠进行了体外和体内研究.
  • 技术包括光成像,RT-qPCR,ELISA,组织病理学,流细胞计和生物信息学分析.

主要成果:

  • PLGA纳米颗粒在鼻腔和肺部表现为长期保留和持续释放.
  • 在体外,PLGA-exo-PIO抑制了炎症,在体内显著改善了UAD症状,减少了炎症细胞和调节了细胞因子 (IFN-γ,IL-10,基因素,IgE,LTC4,IL-4,IL-17).
  • 流细胞测量显示免疫细胞群的变化,包括Th1,Tregs和Bregs的增加,以及Th2,eosinophil和basophil的减少. 生物信息学分析通过诺奇和NF- kB途径支持治疗效果.

结论:

  • 作为一种新疗法,开发了一种PLGA-exo-PIO增强的MSC外体系统.
  • 这种系统可以同时治疗过敏性鼻炎和喘,